Thank you very much. I enjoy searching about Inovio, you can always find something interesting.
Have a great weekend too.
Dr. Collins has been the adviser of Dr. Kim. He joined VGX and helped Dr. Kim with the merger with Inovio Biomedical.
Dr. Collins for 30 years was a managing partner in four DSV partnerships that specialized in early-stage financing of high-technology companies.
I'm sure Dr. Collins helped Dr. Kim with the Roche deal too (about the financial part). He is the expert on this.
Dr. Kim said that Inovio is still in discussions with other pharmas. A few days after, his adviser on this issue, Dr. Collins, made the biggest share purchase of an insider ever in Inovio.
The conclusion is yours....
About the Korean American Society in Biotech and Pharmaceuticals ("KASBP")
The Korean American Society in Biotech and Pharmaceuticals ("KASBP") is a non-profit organization founded in May 2001. The current members include Korean-American professionals working throughout the U.S., mostly in the Biotech or Pharmaceutical field. The member profile includes not only professionals working in 100 pharmaceutical industries (BMS, Novartis, GSK, Merck, Sanofi, J&J, Pfizer, etc.), but also scientists in academics serving universities as faculty members, researchers, post-docs, or graduate students; as well as government employees in the FDA, NIH, and other local and federal government organizations.
KASBP aims to promote scientific recognitions in the community, especially for drug discovery and development. KASBP's activities include annual symposiums to contribute to the advancement of drug discovery, development and other pharmaceutical technology in Korean and U.S. companies. Through a collaboration and networking among the members in Biotech companies, pharmaceutical companies and government funded research centers; KASBP has been helping new drug discovery, technology transfer, drug development and commercialization by Korean companies in Korea and in the U.S markets. One important goal of KASBP is to identify and nurture young Korean-American researchers to become future leaders for Biotech and Pharmaceutical industries in Korea and the U.S. by awarding scholarships.
donallenthompson, beyond what Steven said, read Dr. Kim's words from yesterday's webcast. The potential partners will likely combine their treatments with Inovio's vaccines and electroporation.
Merck is working on a new preventive HPV vaccine, but they still have to do much to improve it.
So, like Roche with its cancer treatments, they could combine Inovio's technology with theirs.
Dr. Kim also implied that they can expand their pipeline to other types of cancer, if a big pharma wants to. So, for any of new preclinical trials we could speculate the interest of a big pharma behind it:
"However we certainly expect additional deals in the future as we are continuing discussions with other large pharmaceutical companies interested in potentials strategic partnerships to advance the development of Inovio SynCon immunotherapy and vaccine products among the many other diseases we have already targeted or able to target."
"Inovio highlighted another new application of the DNA technology in a paper discussing the ability to stimulate blood vessel growth, limb function recovery and survival from limb necrosis and amputation, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease. This result was achieved with Inovio's DNA therapy encoded for hypoxia-inducible factor-1 alpha or HIF-1 alpha. Results from this mice study were published in the Journal of Vascular Surgery.
Patients with peripheral arterial disease have very limited treatment option and this is a multi-billion dollar market opportunity. Inovio's core technology platform had significant growth and additional multi-billion dollar potential in other notable markets and applications.
These other applications represent new opportunities for additional support funding and corporate partnerships."
If a significant movement is a +200% or so then we should wait until HPV results.
But If a significant move is considered a less than +100%, then we should check again stock's performance during the period between April and July: the stock price went from 0.60 to 0.90 before the HIV study, moved by other not scheduled news (Ebola/Marburg, Influenza), plus the expectations for the HIV. The same could happen again. As we waiting for HPV results, other results, preclinical or not, grants etc could occur. Dr. Kim referred to continuing negotiations "we are actively seeking additional grant funding and partnerships".
Considering these possibilities, I think this is the best period to add shares until mid December, like it was in 2012. The bio sector is under pressure also as this was a good year and I don't think Inovio will release any news for the next 20 days (but news still could come from analysts upgrades etc).
I wondered the same one year ago, before 2013 trials, collaborations etc, when it was at 60 cents. It was cheap then too...now I'm not surprised anymore or getting anxious. The Q report is good, the price will go up again. So simple if you aren't a trader.
They don't base their assumptions to the real facts, so they don't have any reason to do something different now.
On the other hand they can't manipulate the share price for the long term, so we will continue to gain if Inovio continue to release such 10-Q and successful trials.
" To build on promising preclinical and clinical data from our universal flu vaccine program, we are actively seeking additional grant funding and partnerships to further develop our potentially paradigm-changing flu products. "
Increased revenues or losses are not so important for an early stage biotech imo.
The prostate cancer and the reference to a future partnership about the flu vaccines is the news I keep so far.
The increase of cash and cash equivalents is very good news also.
Personally I don't care so much about the quarterly profit or loss of a early stage biotech like Inovio. The burn rate and the cash is more important, I see no worries, a dilution is far.
After all these good news during the last monts, my concern was any negative surprises, but there isn't something like this so far.
Nothing unexpected so far. All collaborations and partnerships continue.
Good to know that University of Southampton has indicated that its phase II clinical study of its leukemia vaccine stopped for now because of lack of sponsors and not because of safety issues etc.
All good with Roche, Inovio received the $10 million from them in October.
No surprises, that's good.
Only the seperated reference that Inovio is looking actively for a collaboration about the flu vaccines...maybe they are near to a deal?
I see 10 negative ratings. I guess the 30-names shorter is still here. This is good for us according to the recent past.
Read below bjvhottie62 post to see who's opinion about Inovio they rate. They don't want to face the reality.
To say that you completed my message is not enough. Your info is pivotal. Thank you bjvhottie62.
You must be very confident about your position to joking around all the time. Short or long...